Applied Genetic Technologies C - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AGTC Nasdaq 8731 https://www.agtc.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Applied Genetic Technologies C

AGTC Announces Key Appointments to Leadership Team - Jun 8th, 2022 12:00 pm
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting - Jun 6th, 2022 12:00 pm
AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board - Jun 1st, 2022 12:00 pm
AGTC to Present at the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm
Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months - May 17th, 2022 10:39 am
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa - May 16th, 2022 8:01 pm
AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion - May 10th, 2022 12:00 pm
Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting - May 4th, 2022 12:00 pm
AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy - May 2nd, 2022 8:33 pm
AGTC to Present at Cell & Gene Meeting on the Mediterranean - Apr 14th, 2022 12:00 pm
AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting - Apr 4th, 2022 8:45 pm
AGTC Announces Pricing of Public Offering of Common Stock - Mar 22nd, 2022 12:45 pm
AGTC Announces Proposed Public Offering of Common Stock - Mar 21st, 2022 8:01 pm
AGTC to Participate in Upcoming Investor Conferences - Mar 8th, 2022 9:05 pm
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021 - Feb 14th, 2022 12:00 pm
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia - Feb 8th, 2022 12:00 pm
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022 - Feb 7th, 2022 1:00 pm
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - Jan 11th, 2022 1:00 pm
AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference - Jan 4th, 2022 1:00 pm
AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors - Dec 6th, 2021 1:00 pm